Please wait while the formulary information is being retrieved.
Drug overview for BLENREP (belantamab mafodotin-blmf):
Generic name: belantamab mafodotin-blmf (bal-AN-ta-mab MA-foe-DOE-tin)
Drug class: Antineoplastic Monoclonal Antibodies
Therapeutic class: Antineoplastics
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: belantamab mafodotin-blmf (bal-AN-ta-mab MA-foe-DOE-tin)
Drug class: Antineoplastic Monoclonal Antibodies
Therapeutic class: Antineoplastics
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for BLENREP (belantamab mafodotin-blmf) have been approved by the FDA:
Indications:
Multiple myeloma
Professional Synonyms:
Plasma cell myeloma
Indications:
Multiple myeloma
Professional Synonyms:
Plasma cell myeloma
The following dosing information is available for BLENREP (belantamab mafodotin-blmf):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| BLENREP 70 MG VIAL | Maintenance | Adults infuse 2.5 mg/kg over approximately 30 minute(s) by intravenous route every 3 weeks |
No generic dosing information available.
The following drug interaction information is available for BLENREP (belantamab mafodotin-blmf):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for BLENREP (belantamab mafodotin-blmf):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Lactation |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Pregnancy |
| Reduced visual acuity |
| Thrombocytopenic disorder |
There are 0 moderate contraindications.
The following adverse reaction information is available for BLENREP (belantamab mafodotin-blmf):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 18 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Anemia Disorder of cornea Hypoalbuminemia Increased aspartate transaminase Lymphopenia Thrombocytopenic disorder |
Corneal ulcer Hypercalcemia Hypertension Hypokalemia Hyponatremia Keratitis Kidney disease with reduction in glomerular filtration rate (GFr) Neutropenic disorder Pneumonia Proteinuria Sepsis Tachycardia |
| Rare/Very Rare |
|---|
| None. |
There are 20 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Blurred vision Fatigue Fever Hyperglycemia Nausea Reduced visual acuity |
Anorexia Arthralgia Back pain Constipation Diarrhea Dry eye General weakness Increased alkaline phosphatase Increased creatine kinase level Lethargy Ocular irritation Photophobia Upper respiratory infection Vomiting |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for BLENREP (belantamab mafodotin-blmf):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for BLENREP (belantamab mafodotin-blmf):
WARNING: This medication may cause serious eye problems. Changes to the surface of your eye can lead to dry/itchy eyes, ulcer, or vision changes (such as blurred/decreased vision). Your doctor will have you do eye exams before starting this medication and while you are using it.
To help prevent dry eyes, use preservative-free lubricant eye drops at least 4 times a day as directed. Avoid wearing contact lenses during treatment with this medication unless your doctor tells you otherwise. Tell your doctor right away if you have any vision changes or eye problems during treatment with this medication.
To receive belantamab mafodotin in the United States, you must understand, agree to, and carefully follow the requirements of the REMS Program for this medication. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.
WARNING: This medication may cause serious eye problems. Changes to the surface of your eye can lead to dry/itchy eyes, ulcer, or vision changes (such as blurred/decreased vision). Your doctor will have you do eye exams before starting this medication and while you are using it.
To help prevent dry eyes, use preservative-free lubricant eye drops at least 4 times a day as directed. Avoid wearing contact lenses during treatment with this medication unless your doctor tells you otherwise. Tell your doctor right away if you have any vision changes or eye problems during treatment with this medication.
To receive belantamab mafodotin in the United States, you must understand, agree to, and carefully follow the requirements of the REMS Program for this medication. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.
The following icd codes are available for BLENREP (belantamab mafodotin-blmf)'s list of indications:
| Multiple myeloma | |
| C90.0 | Multiple myeloma |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
Formulary Reference Tool